Literature DB >> 3131059

Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias.

A Cavalli1, A P Maggioni, S Marchi, A Volpi, R Latini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3131059     DOI： 10.2165/00003088-198814030-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  5 in total

Review 1.  Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.

Authors:  R L Woosley; D S Echt; D M Roden
Journal:  Am J Cardiol       Date:  1986-01-31       Impact factor: 2.778

Review 2.  Drug therapy. Flecainide.

Authors:  D M Roden; R L Woosley
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

3.  Interaction of flecainide with digoxin and propranolol.

Authors:  G P Lewis; J L Holtzman
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

4.  Application of a bonded-phase extraction column for rapid sample preparation of flecainide from human plasma for high-performance liquid chromatographic analysis--fluorescence or ultraviolet detection.

Authors:  S F Chang; A M Miller; J M Fox; T M Welscher
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

Review 5.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778
  5 in total
  7 in total

1.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

3.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 5.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

6.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  Flecainide: evidence of non-linear kinetics.

Authors:  G Boriani; E Strocchi; A Capucci; R Callivà; L Frabetti; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.